Thank you for your interest in Glycostem. For members of the press and other interested parties, links on this page are downloadable news releases and images. Collectively, these media kit materials will provide a comprehensive overview of our company, our technology and our achievements in Natural Killer (NK) cells research and development.
In the press
- Biopharma Dealmakers - Nature: Natural killer cells making better cancer immunotherapies
- Biopharma Dealmakers - Nature: Glycostem launches pivotal oncology trial with evolved naked natural killer cells
- Off-the-shelf NK cells in hematologic malignancies and oncology
- Umbilical cord blood NK cells offer multiple advantages for cancer immunotherapy: lessons learned from Glycostem’s orphan drug oNKord®